Sunday, May 18, 2025
5/18/2025
The role of CXCL10 expressing B cells in skin inflammation - Inflammatory skin diseases, such as psoriasis and allergic contact dermatitis, affect a large proportion of the population. B cells that suppress inflammation, termed regulatory B cells (Breg), are key contributors to homeostasis and to limiting inflammation at many sites, including the skin. IL-10 is an important regulatory molecule used by Bregs to constrain T cell responses. The mechanisms used by Bregs to interact with their target T cells have not been defined, and no approaches exist to modulate T cell effector functions in skin and other sites via targeting of B cell properties. Our preliminary data show that IL-10+ Bregs express CXCL10, ligand for the chemokine receptor CXCR3. Effector CD4 and CD8 T cells are the main cell types that express CXCR3 and chemotax toward CXCL10. We hypothesize that Bregs produce CXCL10 to ‘lure’ effector/memory T cells into their vicinity and expose them to IL-10 and potentially other Breg molecules, resulting in dampened T cell responses and decreased inflammation. Alternatively, CXCL10 expressed by effector B cells may amplify the immune response through enhanced T cell recruitment and/or augmentation of T cell and B cell activation by facilitating antigen-specific T-B interactions. To test our hypothesis, we propose two specific aims: Aim 1 will test the role of B-cell expressed CXCL10 during skin inflammation using a mouse model with inducible B-cell restricted CXCL10-deficiency. Under Aim 2 we will reveal the (IL-10+ and IL-10–) B cell subsets that produce CXCL10 during skin inflammation as well as determine the effector and regulatory T cell subsets attracted to skin B cell CXCL10. The gained knowledge will allow us to refine strategies to modulate cutaneous T cell responses in inflammation, infection, and cancer through targeting B cell functions.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).